Endocrine and Metabolic Abnormalities Involved in Obesity
Associated with Typical Antipsychotic Drug Administration

In this study, the authors assessed the endocrine system and glucose tolerance in obese and non-obese women chronically treated with typical antipsychotic drugs (AP). In particular, we tested the hypotheses that these subjects display hypogonadism and increased insulin resistance compared to healthy weight-matched controls, as these abnormalities create a tendency towards excessive body weight gain. Twenty-six AP-treated women were matched with 26 healthy women by age, body mass index and day of the menstrual cycle. The following serum variables were evaluated in each subject: glucose tolerance after an oral glucose overload, insulin, leptin, β-endorphin, reproductive hormones, adrenal steroids and lipids. Compared to controls, AP-treated women displayed significantly higher levels of basal glucose, insulin after 60 min of the glucose overload, prolactin, thyroid stimulating hormone and β-endorphin, with lower levels of C-Peptide, progesterone, 17-OH progesterone, androstenedione and high-density lipoprotein cholesterol. The levels of estradiol, estrone and leptin did not differ between the groups. Thus, women treated with typical AP appeared to display more insulin resistance than healthy controls, predisposing them to excessive weight gain. Insulin sensitivity might be further impaired when the subject switches to atypical AP administration. Metformin and related agents may reduce body weight in these subjects. The high levels of the opiate β-endorphin suggest that opiate antagonists such as naloxone and naltrexone might be useful as well. Even though the luteal phase of the menstrual cycle appears to be severely disturbed, the normal serum levels of estradiol and estrone do not support the proposal derived from animal experimental studies about the use of estrogens or tamoxifen to counteract AP-induced obesity.

References

• 1 Allison D B, Mentore J L, Heo M, Chandler LP, Cappelleri J C, Infante M C, Weiden P J. Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
• 2 Allison D B, Fontaine K R, Heo M, Mentore J L, Cappelleri J C, Chandler L P, Weiden P J, Cheskin L J. The distribution of body mass index among individuals with and without schizophrenia.  J Clin Psychiatry. 1999;  60 215-220
• 3 Ammon H PT, Orci I, Steinke J. Effect of chlorpromazine on insulin release in vivo and in vitro in the rat.  J Pharmacol Exp Ther. 1973;  187 423-429
• 4 Ataya K, Mercado A, Kartaginer J, Abbasi J, Moghissi K S. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia.  Fertil & Steril. 1988;  50 876-881
• 5 Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management.  Acta Psychiat Scand. 1999;  100 3-16
• 6 Baptista T, Parada M A, Herna¿ndez L. Long-term administration of some antipsychotic drugs increases body weight and feeding in rats: Are D₂ dopamine receptors involved?.  Pharmacol Biochem Behav. 1987;  27 399-405
• 7 Baptista T, Alastre T, Contreras Q, Martinez J L, Araujo de Baptista E, Pa¿ez X, Herna¿ndez L. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation.  Pharmacopsychiat. 1997;  30 250-255
• 8 Baptista T, Molina M G, de Quijada M, Calanche I, Acosta A, Pa¿ez X, Martinez J L, Martinez J M, Herna¿ndez L. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy women: relationship with body weight regulation.  Pharmacopsychiatry. 1997;  30 256-262
• 9 Baptista T, Araujo de Baptista E, Altemus M, Weiss S RB, Teneud L, Herna¿ndez L. Tamoxifen prevents sulpiride-induced obesity in rats.  Pharmacol Biochem Behav. 1997;  57 215-222
• 10 Baptista T, Reyes D, Hernández L. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation.  Pharmacol Biochem Behav. 1999;  62 409-417
• 11 Baptista T, Lacruz A, Acosta A, Colasante C, de Quijada M, de Mendoza S, Mendoza J M, Hernandez L. Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats.  Appetite. 2000;  34 77-86
• 12 Baptista T, Lacruz A, Silvera R, Angeles F, Mendoza S, Mendoza J M, Mendoza M T, Herna¿ndez L. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones.  Pharmacopsychiat. 2000;  33 81-88
• 13 Beumont P JV, Gelder M G, Friesen H G, Harris G W, MacKinnin P CB, Mandelbrote B M, Wiles D H. The effects of phenothiazines on endocrine function: I: patients with inappropriate lactation and amenorrhoea.  Brit J Psychiatry. 1974;  124 413-419
• 14 Beumont P JV, Corker C S, Friesen H G, Kolakowska T, Mandelbrote B M, Marshall J, Murray M AF, Wiles D H. The effects of phenothiazines on endocrine function: II: effects in men and post-menopausal women.  Brit J Psychiatry. 1974;  124 420-430
• 15 Brambilla F, Guastalla A, Guerini A, Riggi F, Rovere C, Zanoboni A, Zanoboni-Muciaccia W. Glucose-insulin metabolism in chronic schizophrenia.  Dis Nerv Sys. 1976;  37 98-103
• 16 Bromel T, Blum W F, Zeigler A, Schulz W, Bender M, Fleisbacher C, Remmsschmidth H, Krieg J C, Heberbrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy.  Mol Psychiat. 1998;  3 76-80
• 17 Cabrera R, Mayor P, Ferna¿ndez-Ruiz J, Calle C. Insulin binding and action on adipocytes from female rats with experimentally-induced chronic hyperprolactinemia.  Mol Cell Endocrinol. 1988;  58 167-173
• 18 Correa N, Opler L A, Kay S R, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics.  J Clin Psychopharmacol. 1987;  7 91-95
• 19 Crawford A MK, Beasley C HM, Tollefson G D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration.  Schizophr Res. 1997;  26 41-54
• 20 Dixon L, Weiden P, Delahanty J, Goldberg R, Postgrado L, Lucksted A, Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples.  Schizophr Bull. 2000;  26 903-912
• 21 Dorrington J, Gore-Langton I. Prolactin inhibits oestrogen synthesis in the ovary.  Nature. 1981;  290 600-602
• 22 Eckel R H. Insulin resistance: an adaptation for weight maintenance.  Lancet. 1992;  340 1452-1453
• 23 Erhardt V R, Goldman M B. Adverse Endocrine Effects. In: Keshavan MS, Kennedy JS, editors Drug-Induced Dysfunction in Psychiatry. New York; Hemisphere Publishing Corporation 1992: 296-297
• 24 Erle G, Basso M, Federspil G, Sicolo N, Scandellari C. Effect of chlorpromazine on blood glucose and plasma insulin in man.  Eur J Clin Pharmacol. 1977;  11 15-18
• 25 Ferreira M F, Sobrinho L G, Santos M A, Sousa M F, Uvnas-Mogberg K. Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone.  Psychoneuroendocrinol. 1998;  23 1005-1013
• 26 Fontbonne A, Charles M A, Juhan Vague I, Bard J M, Andre¿ P, Isnard F, Cohen J M, Granmottet P, Vague P, Safer M E, Eschwege E. The effects of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.  Diabetes Care. 1996;  19 920-926
• 27 Foss M C, Paula F J, Paccola G M, Piccinato C E. Peripheral glucose metabolism in human hyperprolactinemia.  Clin Endocrinol. 1995;  43 721-726
• 28 Genazzani A R, Facchinetti F, Petraglia F, Pintor C, Corda R. Hyperendorphinemia in obese children and adolescents.  J Clin Endocrinol Metab. 1986;  62 36-40
• 29 Gerardo-Gettens T, Moore B J, Stern J S, Horwitz B A. Prolactin stimulates food intake in a dose-dependent manner.  Am J Physiol. 1989;  256 R276-R280
• 30 Giusti G, Bassi F, Forti G. Effects of prolactin on androgens secretion by the human adrenal cortex. In: Harter RC, editors Progress in Prolactin Physiology and Pathology. Amsterdam; Elsevier 1978
• 31 Givens J R. Reproductive and hormonal alterations in obesity. In: Bjorntorp P, Brodoff BN, eds. Obesity. Philadelphia; J. B. Lippincott Company 1992: 540-550
• 32 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.  Clin Endocrinol. 1998;  48 547-553
• 33 Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial on the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.  Br J Psychiatry. 1988;  153 208-213
• 34 Gopalaswamy A K, Morgan R. Too many chronic mentally disabled patients are too fat.  Acta Psychiat Scand. 1985;  72 254-258
• 35 Green A I, Patel J K, Goisman R M, Allison D B, Blackburn G. Weight gain from novel antipsychotic drugs: need for action.  Gen Hosp Psychiat. 2000;  22 224-235
• 36 Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlquvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.  J Clin Psychiatry. 1998;  59 294-299
• 37 Hartman D S, Civelli O. Molecular attributes of dopamine receptors: new potential for antipsychotic drug development.  Ann Med. 1996;  28 211-219
• 38 Kissebah A H, Krakower G R. Regional adiposity and morbidity.  Physiol Rev. 1994;  74 761-811
• 39 Kopelman P G. Obesity as a medical problem.  Nature. 2000;  404 635-643
• 40 Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs.  Am J Psychiat. 1999;  156 314-321
• 41 Lacruz A, Baptista T, de Mendoza S, Mendoza-Guillén J M, Hernández L. Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment.  Mol Psychiat. 2000;  5 70-76
• 42 Leibowitz S F, Hoebel B G. Behavioral Neuroscience of Obesity. In: Bray GA, Bouchard C, James WPT, eds. Handbook of Obesity. New York; Marcel Dekker, Inc 1998: 313-358
• 43 Lobo R, Kletzky O. Normalization of androgen and sex hormone binding globulin levels after treatment of hyperprolactinemia.  J Clin Endocrinol Metab. 1982;  56 562-568
• 44 MacNatty K P, Sawers R S, McNeilly A S. A possible role for prolactin in control of steroid secretion by the human Graafian follicle.  Nature. 1975;  250 653-655
• 45 Matsuda M, Mori T. Effect of estrogen on hyperprolactinemia-induced glucose intolerance in SHN mice.  Proc Soc Exp Biol Med. 1996;  212 243-247
• 46 Matsuzaki T, Azuma K, Irahara M, Yasui T, Aono T. Mechanism of anovulation in hyperprolactinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin.  Fertil Steril. 1994;  62 1143-1149
• 47 Melkerson K I, Hulting A L, Brismar K E. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.  J Clin Psychiatry. 1999;  60 783-791
• 48 Melkerson K I, Hulting A L, Brismar K E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.  J Clin Psychiatry. 2000;  61 742-749
• 49 Meltzer H Y, Goode D, Schyve P M, Young M, Fang V. Effect of clozapine on human serum prolactin levels.  Am J Psychiatry. 1979;  136 1550-1555
• 50 Moore B J, Gerardo-Gettens T, Horwitz B A, Stern J S. Hyperprolactinemia stimulates food intake in the female rat.  Brain Res Bull. 1986;  17 563-569
• 51 Murialdo G, Galimberti C A, Gianelli M V, Rollero A, Polleri A, Copello F, Magri F, Ferrari E, Sampaolo P, Manni R, Tartara A. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy.  Clin Neuropharmacol. 1998;  21 52-58
• 52 Oades R D, Schepker R. Serum gonadal steroid hormones in young schizophrenic patients.  Psychoneuroendocrinology. 1994;  19 373-385
• 53 Parada M A, Herna¿ndez L, Pa¿ez X, Baptista T, Puig de Parada M, Quijada M. Mechanism of the sulpiride-induced obesity in rats.  Pharmacol Biochem Behav. 1989;  33 45-50
• 54 Paykel E S, Mueller P S, De La Vergne P M. Amitryptiline, weight gain and carbohydrate craving: a side effect.  Brit J Psychiat. 1973;  123 501-507
• 55 Peiris A, Kissebah A. Endocrine abnormalities in morbid obesity.  Gastroenterol Clin N Amer. 1987;  16 389-398
• 56 Percheron C, Colette C, Mariano-Goulart D, Avignon A, Capeyron O, Boniface H, Bressot N, Monnier L. Relationship between insulin sensitivity, obesity, body fat distribution and beta-endorphinemia in obese women.  Int J Obes Relat Metab Disord. 1998;  22 143-148
• 57 Poretsky L, Cartin M F. The gonadotropic function of insulin.  Endocrinol Rev. 1987;  8 132-136
• 58 Ravussin E. Metabolic differences and the development of obesity.  Metabolism. 1995;  44 12-14
• 59 Reiss F M, Ribeiro de Oliveira J R, Guerra R M, Reiss A M, Coimbra C C. Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress.  Life Sci. 1996;  58 155-161
• 60 Rinieris P, Markianos M, Hatzimanolis J, Stefanis C. A psychoendocrine study in male paranoid schizophrenic patients with delusional ideas of homosexual content.  Acta Psychiatr Scand. 1985;  3 309-314
• 61 Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vitro.  Diabetol. 1985;  28 138-142
• 62 Schimmelbusch W H, Mueller P S, Sheps J. The positive correlation between insulin resistance and duration of hospitalization in untreated schizophrenia.  Brit J Psychiatry. 1971;  118 429-436
• 63 Schultz S K, Arndt S, Ho B C, Oliver S E, Andreasen N C. Impaired glucose tolerance and abnormal movements in patients with schizophrenia.  Am J Psychiatry. 1999;  156 640-642
• 64 Schwartz M W, Woods S C, Porte D, Seeley R J, Baskin D G. Central nervous system control of food intake.  Nature. 2000;  404 661-671
• 65 Serri O, Beauregard H, Rasio E, Hardy J. Decreased sensitivity to insulin in women with microprolactinomas.  Fertil Steril. 1986;  45 572-574
• 66 Silverstone T, Finchman J, Wells B, Kyriakides M. The effect of the dopamine receptor-blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man.  Neuropharmacology. 1980;  19 1235-1237
• 67 Sletten I W, Gershon S. The effect of chlorpromazine on water and electrolyte balance.  J Nerv Ment Dis. 1966;  142 25-31
• 68 Sociedad Venezolana de Cardiología . Recomendaciones de ILIB para el diagnóstico y tratamiento de las dislipidemias en Latinoamérica.  Avances Cardiología. 1994;  XIV ( Suppl. 1) 12-15
• 69 Stanton J M. Weight gain associated with neuroleptic medication: a review.  Schiz Bull. 1995;  21 463-472
• 70 Taylor D M, Mcaskill R. Atypical antipsychotics and weight gain - a systematic review.  Acta Psychiat Scand. 2000;  101 416-432
• 71 Tabata H, Kikuoka M, Kikuoka H, Bessho H, Hirayama J, Hanabusa T, Kubo K, Momotami Y, Sanke T, Nanjo K. Characteristics of diabetes melitus in schizophrenic patients.  J Med Assoc Thai. 1987;  70 (Suppl 2) 90-93
• 72 Vaccarino F J, Mogil J S, Stinus L. Chronic dopamine antagonism facilitates opiate-induced feeding.  J Psychiat Neurosci. 1995;  20 210-214
• 73 Velasquez E, Mendoza S, Harner T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.  Metabolism. 1994;  5 647-654
• 74 Wade G N, Schneider J E. Metabolic fuels and reproduction in female mammals.  Neurosci Biobehav Rev. 1992;  16 235-272
• 75 Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat.  Nature. 1998;  393 684-688
• 76 West J B. Physiological Basis of Medical Practice, 12^th Edition. Baltimore; Williams & Wilkins 1991: Chap. 53
• 77 Wirshing D A, Spellberg B J, Erhart S M, Marder S R, Wirshing W C. Novel antipsychotics and new onset diabetes.  Biol Psychiatry. 1998;  44 778-783
• 78 Wirshing D A, Wirshing W C, Kysar L, Berisford M A, Goldstein D, Pashdag J, Mintz J, Marder S R. Novel antipsychotics: comparison of weight gain liabilities.  J Clin Psychiatry. 1999;  60 358-363
• 79 Woods S C, Seeley R J, Porte D, Schwartz M W. Signals that regulate food intake and energy homeostasis.  Science. 1998;  280 1378-1382
• 80 Yazici K M, Erbas T, Yazici A H. The effect of clozapine on glucose metabolism.  Exp Clin Endocrinol Diabetes. 1998;  106 475-477
• 81 Zimmermann U, Rechlin T H, Plaskacewicz G J, Barocka A, Wildt L, Kaschka P. Effect of Naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study.  Biol Psychiat. 1997;  41 747-749